secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cryoport, Inc. (CYRX)
CIK:        0001124524
Form:       8-K
Filed at:   2022-02-24T23:59:59+00:00
Accession:  0001104659-22-026741
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cryoport FY2021 revenue $222.6M (+183% YoY); Q4 net loss $260.1M on $251.8M debt extinguishment
--------------------------------------------------------------------------------

- FY2021 revenue $222.6M (+183% YoY); organic revenue from Cryoport Systems & CRYOGENE +40%.
- Q4 revenue $56.4M (+17% YoY); Biopharma/Pharma revenue $46.3M (+18%).
- Net loss Q4 $260.1M incl $251.8M non-cash debt extinguishment; Adj. EBITDA $0.8M.
- Cash & short-term investments $628.8M at Dec 31, 2021; placed $402.5M 0.75% convertible notes.
- Supports record 602 clinical trials (273 Phase 2, 74 Phase 3); fire at MVE facility expected Q1 impact $4-5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124524/000110465922026741/0001104659-22-026741-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124524/000110465922026741/tm227658d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-026741

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer